Nurix Therapeutics 

Yahoo Finance • 7 days ago

Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge

VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity InsiderNews Commentary – The U.S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], driven by a fundamental shift in how physi... Full story

Yahoo Finance • 10 days ago

Wells Fargo Reaffirms a Buy Rating on Nurix Therapeutics (NRIX), Sets a $30 PT

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best small cap stocks to buy with huge upside potential. On December 16, Wells Fargo analyst Derek Archila reaffirmed a Buy rating on Nurix Therapeutics, Inc. (NASDAQ:NRIX) with a $30 pr... Full story

Yahoo Finance • 16 days ago

Cathie Wood tilts toward Robinhood, Bitcoin ETFs, trims Tesla, Iridium

[Bitcoin 2022 Conference Draws Cryptocurrency Industry Professionals And Investors To Miami] Marco Bello Cathie Wood’s ARK Investment Management chopped its holdings in EV maker Tesla (TSLA [https://seekingalpha.com/symbol/TSLA]) and sate... Full story

Yahoo Finance • 23 days ago

Kymera Rockets, Pulling Nurix Higher. Does It Have The Next Dupixent?

Kymera Therapeutics could have the next Dupixent, analysts said Monday, as shares skyrocketed on promising test results in eczema. Continue Reading... Full story

Yahoo Finance • 25 days ago

Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition

Objective response rate (ORR) of 83% including two complete responses in CLL patients in Phase 1a study with median progression free survival (PFS) of 22.1 months across all doses tested Emerging data from randomized Phase 1b cohorts poin... Full story

Yahoo Finance • 30 days ago

Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition

SAN FRANCISCO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors

SAN FRANCISCO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted protein degradation medicines i... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Announces $250.0 Million Registered Offering of Common Stock

SAN FRANCISCO, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines in... Full story

Yahoo Finance • 2 months ago

Nurix Initiates DAYBreak™ Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia

600 mg once daily bexobrutideg oral dose cleared by global regulators for pivotal monotherapy trials in relapsed/refractory chronic lymphocytic leukemia (r/r CLL) Phase 2 DAYBreak trial initiated for potential Accelerated Approval New pr... Full story

Yahoo Finance • 2 months ago

Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Oncology (ESMO) Congress

NX-1607 demonstrated on-target peripheral immune activation characteristic of an active immune-oncology agent with a novel immune checkpoint mechanism distinct from PD-1/PD-L1 therapies NX-1607 demonstrated evidence of monotherapy anti-tu... Full story

Yahoo Finance • 3 months ago

Stocks Climb as Dovish Fed Comments Knock Bond Yields Lower

The S&P 500 Index ($SPX [https://www.barchart.com/futures/quotes/$SPX/overview]) (SPY [https://www.barchart.com/etfs-funds/quotes/SPY/overview]) today is up +0.32%, the Dow Jones Industrials Index ($DOWI [https://www.barchart.com/futures/q... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics GAAP EPS of -$1.03 misses by $0.11, revenue of $7.9M misses by $4.33M

* Nurix Therapeutics press release [https://seekingalpha.com/pr/20261446-nurix-therapeutics-reports-third-quarter-2025-financial-results-and-provides-a-corporate] (NASDAQ:NRIX [https://seekingalpha.com/symbol/NRIX]): Q3 GAAP EPS of -$1.0... Full story

Yahoo Finance • 3 months ago

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration... Full story

Yahoo Finance • 4 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, t... Full story

Yahoo Finance • 6 months ago

Nurix Therapeutics price target lowered to $34 from $36 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Nurix Therapeutics (NRIX) to $34 from $36 and keeps a Buy rating on the shares. Nurix last week reported a Q2 net loss of (52c) per share, slightly narrower than the firm’s previously esti... Full story

Yahoo Finance • 6 months ago

Morgan Stanley lowers Nurix stock price target to $16 on higher spend

Investing.com - Morgan Stanley lowered its price target on Nurix (NASDAQ:NRIX) to $16.00 from $17.00 on Monday, while maintaining an Equalweight rating on the biotechnology company’s stock. With the stock currently trading at $12.72, analy... Full story

Yahoo Finance • 6 months ago

Goldman Sachs initiates Nurix stock with Buy rating, $182 price target

Investing.com - Goldman Sachs initiated coverage on Nurix (NASDAQ:NRIX) with a Buy rating and set a price target of $182.00. Currently trading at $13.18, the stock has shown significant volatility with a beta of 2.15. According to Investin... Full story

Yahoo Finance • 6 months ago

Nurix earnings beat by $0.19, revenue topped estimates

Investing.com - Nurix (NASDAQ: NRIX) reported second quarter EPS of $-0.52, $0.19 better than the analyst estimate of $-0.71. Revenue for the quarter came in at $44.06M versus the consensus estimate of $16.9M. Nurix’s stock price closed a... Full story